March 27, 2020—Biocare Medical launched seven novel IVD IHC antibody markers for clinical diagnostics and research applications. This launch focuses on several immuno-oncology markers, critical in aiding early-stage cancer drug developments and patient treatment. The company redeveloped its S100 protein antibody and released one mouse monoclonal and five novel rabbit monoclonal antibodies in the immuno-oncology space: CTLA-4 [CAL49], GITR [CAL8], LAG3 [CAL26], PD-1 [CAL20], CD22 (M) [BLCAM/1796], and E-cadherin [CDH1/2208R].
“We are proud to be able to launch novel, IVD IHC markers that meet the highest standards in cancer diagnostics. This commitment to quality ensures Biocare is providing the best diagnostic and research utility possible,” Jason Ramos, PhD, vice president of reagent research and development at Biocare Medical, said in a press release.